Johnson & Johnson Price to Free Cash Flow Ratio 2010-2022 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-01-27 |
168.23 |
|
24.75 |
| 2022-09-30 |
162.32 |
$6.80 |
23.88 |
| 2022-06-30 |
175.20 |
$7.60 |
23.04 |
| 2022-03-31 |
173.83 |
$1.34 |
129.84 |
| 2021-12-31 |
166.70 |
$2.68 |
62.11 |
| 2021-09-30 |
156.34 |
$3.92 |
39.91 |
| 2021-06-30 |
158.53 |
$2.17 |
73.00 |
| 2020-12-31 |
149.58 |
$7.67 |
19.49 |
| 2020-09-30 |
140.51 |
$6.91 |
20.34 |
| 2020-06-30 |
131.85 |
$6.65 |
19.83 |
| 2020-03-31 |
122.09 |
$8.50 |
14.36 |
| 2019-12-31 |
134.94 |
$8.64 |
15.62 |
| 2019-09-30 |
118.86 |
$9.35 |
12.72 |
| 2019-06-30 |
127.95 |
$8.74 |
14.64 |
| 2019-03-31 |
127.55 |
$8.04 |
15.86 |
| 2018-12-31 |
116.98 |
$7.97 |
14.69 |
| 2018-09-30 |
124.45 |
$7.48 |
16.64 |
| 2018-06-30 |
108.57 |
$7.70 |
14.10 |
| 2018-03-31 |
113.82 |
$7.36 |
15.46 |
| 2017-12-31 |
123.31 |
$7.14 |
17.26 |
| 2017-09-30 |
114.05 |
$7.11 |
16.04 |
| 2017-06-30 |
115.31 |
$6.62 |
17.41 |
| 2017-03-31 |
107.85 |
$6.33 |
17.04 |
| 2016-12-31 |
99.12 |
$6.03 |
16.45 |
| 2016-09-30 |
100.93 |
$9.36 |
10.79 |
| 2016-06-30 |
102.95 |
$9.12 |
11.29 |
| 2016-03-31 |
91.19 |
$9.58 |
9.52 |
| 2015-12-31 |
85.95 |
$11.08 |
7.75 |
| 2021-03-31 |
157.18 |
$6.49 |
24.23 |
| 2015-09-30 |
77.54 |
$6.13 |
12.65 |
| 2015-06-30 |
80.33 |
$6.80 |
11.81 |
| 2015-03-31 |
82.31 |
$6.56 |
12.55 |
| 2014-12-31 |
84.97 |
$6.85 |
12.40 |
| 2014-09-30 |
86.05 |
$6.76 |
12.74 |
| 2014-06-30 |
83.89 |
$5.83 |
14.40 |
| 2014-03-31 |
78.22 |
$5.49 |
14.24 |
| 2013-12-31 |
72.41 |
$4.96 |
14.59 |
| 2013-09-30 |
68.07 |
$4.94 |
13.79 |
| 2013-06-30 |
66.92 |
$4.71 |
14.20 |
| 2013-03-31 |
63.06 |
$4.64 |
13.59 |
| 2012-12-31 |
53.79 |
$4.97 |
10.83 |
| 2012-09-30 |
52.42 |
$5.02 |
10.45 |
| 2012-06-30 |
50.93 |
$5.05 |
10.08 |
| 2012-03-31 |
49.25 |
$4.83 |
10.20 |
| 2011-12-31 |
48.54 |
$4.59 |
10.57 |
| 2011-09-30 |
46.70 |
$4.62 |
10.10 |
| 2011-06-30 |
48.35 |
$4.71 |
10.27 |
| 2011-03-31 |
42.70 |
$4.72 |
9.05 |
| 2010-12-31 |
44.17 |
$5.21 |
8.48 |
| 2010-09-30 |
43.87 |
$5.76 |
7.61 |
| 2010-06-30 |
41.43 |
$5.69 |
7.28 |
| 2010-03-31 |
45.32 |
$5.50 |
8.24 |
| 2009-12-31 |
44.43 |
$5.15 |
8.63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$441.560B |
$94.943B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
